Developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders.
External link for MDI Therapeutics, Inc.
46430 Peary Ct.
Novi, MI 48377, US
MDI Therapeutics, Inc. reposted this
Pleased to announce that we have dosed the first participants in a Phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of MDI-2517, a potent small molecule inhibitor of plasminogen activator inhibitor 1 (PAI-1). https://lnkd.in/g_Te6kpD
Pleased to announce that we have dosed the first participants in a Phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of MDI-2517, a potent small molecule inhibitor of plasminogen activator inhibitor 1 (PAI-1). https://lnkd.in/g_Te6kpD